Patents by Inventor Zakhar Nudelman

Zakhar Nudelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210330703
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.
    Type: Application
    Filed: May 14, 2021
    Publication date: October 28, 2021
    Inventors: Doron FRIEDMAN, Yair ALSTER, Omer RAFAELI, Shimon AMSELEM, Zakhar NUDELMAN
  • Publication number: 20210315803
    Abstract: Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.
    Type: Application
    Filed: September 5, 2019
    Publication date: October 14, 2021
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Michael FRIEDMAN, David KIRMAYER, Zakhar NUDELMAN, Amnon HOFFMAN, Eran LAVY, Ayala BAR-HAI, Irith GATI
  • Patent number: 11040062
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 22, 2021
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Doron Friedman, Yair Alster, Omer Rafaeli, Shimon Amselem, Zakhar Nudelman
  • Publication number: 20200281966
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.
    Type: Application
    Filed: April 13, 2017
    Publication date: September 10, 2020
    Inventors: Doron FRIEDMAN, Yair ALSTER, Omer RAFAELI, Shimon AMSELEM, Zakhar NUDELMAN
  • Publication number: 20200179305
    Abstract: Described herein are compositions and methods for treating hyperkeratosis disorders such as dandruff, psoriasis, acne vulgaris, warts, corns, calluses, palmoplantar keratodermas, ichthyosis, seborrheic dermatitis, meibomian gland dysfunction, HPV infection, lichen planus, aclinic keratosis, seborrheic keratosis, etc. Said compositions comprise a selenium-containing amino acid as keratolytic agent, and are topically administered to the skin or eyelid margin of the patient. In some embodiments, the composition comprises a selenium-containing amino acid such as selenium methionine or selenium cysteine formulated in a ophthalmic, dermatological, or cosmetic dosage form.
    Type: Application
    Filed: April 18, 2017
    Publication date: June 11, 2020
    Inventors: Yair ALSTER, Omer RAFAELI, Doron FRIEDMAN, Zakhar NUDELMAN
  • Patent number: 10485792
    Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: November 26, 2019
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michael Friedman, Rakefet Czernimski, Silvio Gutkind, Doron Steinberg, Irith Gati, Zakhar Nudelman
  • Publication number: 20130018069
    Abstract: The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a sustained release drug delivery system comprising a drug for the treatment of this cancer or for the prevention of said lesions, and at least one polymer, such that said system is attached to a surface in the oral cavity and remains attached thereto for at least 1 hour, accompanied by release of the drug and maintaining an effective therapeutic concentration thereof in the cavity, for at least 1 hour. Further are disclosed a sustained release drug delivery system and a liquid precursor varnish composition to this system.
    Type: Application
    Filed: August 25, 2010
    Publication date: January 17, 2013
    Applicant: YISSUM Research Development Company of the Hebrew University of Jerusalem, LTD
    Inventors: Michael Friedman, Rakefet Czernimski, Silvio Gutkind, Doron Steinberg, Irith Gati, Zakhar Nudelman